SCHEMBL207531

SCHEMBL207531

Fc1ccc2[nH][c]cc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 2/20 0.50
KDM4E B2RXH2 2/20 0.41
DAO P14920 2/20 0.41
PDPK1 O15530 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
APEX1 P27695 1/20 0.41
CYP2C19 P33261 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2A6 P11509 1/20 0.41
FLT3 P36888 2/20 0.37
MAPT P10636 1/20 0.37
CYP1A1 P04798 2/20 0.36
GPR84 Q9NQS5 1/20 0.35
ACHE P22303 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207104 0.84 AHR (0.48) AHRKDM4EDAOPDPK1ALDH1A1
SCHEMBL700070 0.73 TNKS2 (0.40) AHRKDM4EMAPT
SCHEMBL207627 0.73 KEAP1 (0.51) KDM4EDAOALDH1A1LMNAHPGD
SCHEMBL208359 0.71 CYP1A2 (0.48) KDM4EDAOALDH1A1HPGDHSD17B10
SCHEMBL207489 0.71 F7 (0.50) AHRKDM4EDAOALDH1A1LMNA
SCHEMBL207737 0.71 CYP2A6 (0.50) AHRKDM4EPDPK1ALDH1A1LMNA
SCHEMBL577522 0.71 KIF11 (0.43) KDM4EALDH1A1HSD17B10KIF11
SCHEMBL4693784 0.71 MEN1 (0.31)
SCHEMBL3059466 0.70 GPR84 (0.44) ALDH1A1TDP1GPR84
SCHEMBL11905567 0.69 TRPA1 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201911-A Compounds and their use as GPR183 inhibitors 南京艾美斐生物医药科技有限公司 2024-06-14 CN claimed
CN-117503766-B Application of PLD inhibitor in preparation of medicine for treating spinal cord injury 中国康复研究中心 2024-04-26 CN claimed
CN-117503766-A Application of PLD inhibitor in preparation of medicine for treating spinal cord injury 中国康复研究中心 2024-02-06 CN claimed
WO-2023066190-A1 COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) 2023-04-27 WO claimed
EP-3321262-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2021-01-13 EP claimed
CN-106349217-B Serine/threonine kinase inhibitors 阵列生物制药公司 2020-08-28 CN claimed
EP-3321262-A1 SERINE/THREONINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2018-05-16 EP claimed
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-05-10 US claimed
US-20160052913-A1 SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED 2016-02-25 US claimed
EP-2791120-B1 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-02-24 EP claimed
US-20030162784-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2003-08-28 US claimed
WO-2003049735-A1 CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS ELI LILLY AND COMPANY (US) 2003-06-19 WO claimed
WO-2003050109-A1 ALANYL-PIPERIDINE HETEROCYCLIC DERIVATIVES USEFUL AGAINST CARDIOVASCULAR DISEASES ELI LILLY AND COMPANY (US) 2003-06-19 WO claimed
EP-1303506-A1 6-HETEROARYLPHENANTHRIDINES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-04-23 EP claimed
WO-2003010160-A2 1-GLYCINYL-4 (METHYLPIPERIDIN-4-YL) PIPERAZINES AND -PIPERRIDINES AS FACTOR XA ANTAGONISTS ELI LILLY AND COMPANY (US) 2003-02-06 WO claimed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP claimed
US-20020143017-A1 Pyridazinone aldose reductase inhibitors MYLARI BANAVARA L (US) 2002-10-03 US claimed
WO-2002048102-A2 ISOCOUMARIN INHIBITING PRODUCTION OF AMYLOID PEPTIDE, PREPARATION, COMPOSITIONS CONTAINING SAME AND USES TROPHOS (FR) 2002-06-20 WO claimed
WO-2002006270-A1 NOVEL 6-HETEROARYLPHENANTHRIDINES ALTANA PHARMA AG (DE) 2002-01-24 WO claimed
US-5128346-A Cholecystokinin antagonists ABBOTT LABORATORIES (US) 1992-07-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052913-A1 SUBSTITUTED BENZIMIDAZOLES AS NOCICEPTIN RECEPTOR MODULATORS OPRL1, OPRK1, OPRM1 AHR 788/4885KDM4E 1692/4885DAO 1737/4885
US-20030162784-A1 Pyridazinone aldose reductase inhibitors SLC5A1, ALDOA, AKR1B1 AHR 3095/4885KDM4E 2331/4885DAO 1327/4885
US-20020143017-A1 Pyridazinone aldose reductase inhibitors SLC5A1, AKR1B1, AKR1D1 AHR 2958/4885KDM4E 2148/4885DAO 1439/4885
US-20180127393-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K11, TTBK1 AHR 4684/4885KDM4E 3484/4885DAO 2160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.